ClinicalTrials.gg
RecruitingNCT05199688SAkuraSunUpdated Oct 1, 2026

A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

A Phase 3 interventional study of Satralizumab in Neuromyelitis Optica Spectrum Disorder and NMOSD, sponsored by Hoffmann-La Roche. Recruiting at 14 sites in 9 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 1, 2026Eligibility revisedPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
2 Years to 11 Years
Sex
All
01

Study summary

This study will primarily evaluate the pharmacokinetics of satralizumab in pediatric patients aged 2-11 years with anti-aquaporin-4 (AQP4) antibody seropositive neuromyelitis optica spectrum disorder (NMOSD). Efficacy, safety, tolerability, and pharmacodynamics will be evaluated in a descriptive manner, given the small number of patients who will be enrolled in this study.

02

Conditions studied

  • Neuromyelitis Optica Spectrum Disorder
  • NMOSD

Browse trials for

03

In context

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

This study's planned enrollment of 8 is below the median of 29 across 108 interventional studies indexed under Neuromyelitis Optica.

Browse Neuromyelitis Optica studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.

Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age at screening 2-11 years, inclusive
  • Body weight at screening >=10 kg
  • For female patients of (postmenarchal): agreement to either remain completely abstinent (refrain from heterosexual intercourse) or to use a reliable means of
  • Diagnosed as having NMOSD with AQP4 antibody seropositive status as defined by the Wingerchuk 2015 criteria Clinical evidence of at least one documented attack (including first attack) in the last year prior to screening:

    • Documented history of a positive anti-AQP4 antibody test or a positive anti-AQP4 antibody test at screening;
  • Neurological stability for >=30 days prior to baseline
  • Expanded Disability Status Scale (EDSS) 0 to 6.5
  • For participants receiving a baseline treatment and planning to continue on these therapies, treatment must be at stable dose for 4 weeks prior to baseline

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Evidence of other demyelinating disease mimicking NMOSD
  • Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection at baseline
  • Evidence of chronic active or C
  • Evidence of untreated latent or active tuberculosis (TB)
  • Receipt of a live or within 6 weeks prior to baseline
  • History of severe allergic reaction to a biologic agent
  • IVIg or subcutaneous Ig (SCIg) within 4 weeks prior to enrollment/Day 1
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Participants with body weight ≥10kg to <20kg

    Satralizumab will be administered SC Q6W in a cohort of at least 2 evaluable patients

    Drug: Satralizumab

  • Experimental
    Cohort 2 Participants with body weight ≥20kg to <40kg

    Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.

    Drug: Satralizumab

  • Experimental
    Cohort 3 Participants with body weight ≥40kg

    Satralizumab will be administered SC at Weeks 0, 2, 4, and Q4W thereafter.

    Drug: Satralizumab

Interventions

  • Participants will receive satralizumab treatment for a minimum of 48 weeks and then will have the opportunity to enter an optional satralizumab extension (OSE) period.

06

What researchers measure

Primary outcomes

  1. Summary of Observed Serum Concentration of Satralizumab

    Time frame: Week 48

  2. Apparent Clearance [CL/F] of Satralizumab

    Time frame: Week 48

  3. Apparent Volume of Distribution [V/F] of Satralizumab

    Time frame: Week 48

  4. Area Under the Concentration-time Curve [AUC] of Satralizumab

    Time frame: Week 48

Secondary outcomes

  1. Proportion of Relapse-free Participants by Week 48

    Time frame: Week 48

  2. Annualized Relapse Rate (ARR), defined as the average number of relapses for each year of the study

    Time frame: Week 48

  3. Time to First Relapse (TFR) after enrollment, defined as the time from enrollment until the first occurrence of relapse, as determined by the investigator

    Time frame: Week 48

  4. Time to Relapse Requiring Rescue Therapy

    Time frame: Week 48

  5. Change from baseline in Expanded Disability Status Scale (EDSS) at Weeks 24 and 48

    Time frame: Baseline, Week 24, Week 48

  6. Change from Baseline in Visual Acuity at Weeks 24 and 48

    Time frame: Baseline, Week 24, Week 48

  7. Change from Baseline in FACES Pain Rating Scale at Weeks 24 and 48

    Time frame: Baseline, Week 24, Week 48

  8. Change from Baseline in EuroQol 5-Dimension, Youth (EQ-5D-Y) Score and its Proxy at Weeks 24 and 48

    Time frame: Baseline, Week 24, Week 48

  9. Incidence and Severity of Adverse Events

    Time frame: Week 48

07

Study locations

13 of 14 sites recruiting
  • Children's Hospital Colorado.
    Denver, Colorado 80218-1007, United States
    Recruiting
  • Hospital de Pediatría S.A.M.I.C.- Prof. Dr. Juan P. Garrahan
    Ciudad Autonoma Buenos Aires, C1249ABN, Argentina
    Recruiting
  • Clinica Universitaria Reina Fabiola
    Córdoba, X5004FHP, Argentina
    Recruiting
  • Guangzhou Women and Children's Medical Center
    Guangzhou, Guangdong 510120, China
    Recruiting
  • Children's Hospital of Fudan University
    Shanghai, Shanghai Municipality 201102, China
    Recruiting
  • Centre Hospitalier Universitaire de Bicêtre
    Le Kremlin-Bicêtre, Val-de-Marne 94275, France
    Recruiting
  • IRCCS Ospedale Pediatrico Bambino Gesù - INCIPIT - PIN
    Rome, Lazio 00165, Italy
    Recruiting
  • Fondazione Istituto Neurologico Mondino IRCCS
    Pavia, Lombardy 27100, Italy
    Recruiting
  • Grupo Medico Camino
    DF, Mexico CITY (federal District), Mexico
    Recruiting
  • Hospital Infantil de Mexico Federico Gomez
    Mexico City, Mexico CITY (federal District) 06720, Mexico
    Recruiting
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-214, Poland
    Active, not recruiting

    Not enrolling at this site.

  • Instytut "Pomnik - Centrum Zdrowia Dziecka"
    Warsaw, 04-730, Poland
    Recruiting
  • Kocaeli University Research and Application Hospit
    Kocaeli, 6810, Turkey (Türkiye)
    Recruiting
  • Great Ormond Street Hospital for Children
    London, WC1N 3JH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2021
First posted
Jan 20, 2022
StartActual
May 6, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Sep 12, 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 Mexico, 1 Poland)
  • Hospital Infantil de Mexico Federico Gomez · Mexico City, Mexico
  • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
Show 1 removed
  • Uniwersyteckie Centrum Kliniczne · Gda?sk, Poland
Oct 1, 2026
Eligibility
2 inclusion criteria edited, 1 added; 1 exclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedDocumented history of a positive anti-AQP4 antibody test or a positive anti-AQP4 antibody test at screening;
  • EditedNeurological stability for >=30 days prior to both screening and baseline
  • EditedFor patientsparticipants receiving a baseline immunosuppressant treatment and planning to continue on these therapies, treatment must be at stable dose for 4 weeks prior to baseline
Exclusion criteria
  • AddedIVIg or subcutaneous Ig (SCIg) within 4 weeks prior to enrollment/Day 1
Oct 1, 2026
Primary outcomes
4 edited
What changed in the outcomes
  • EditedSummary of observed serum concentration [Cthrough]Observed Serum Concentration of satralizumabSatralizumabTime frame: Week 48
  • EditedApparent clearanceClearance [CL/F] of satralizumabSatralizumabTime frame: Week 48
  • EditedApparent volumeVolume of distributionDistribution [V/F] of satralizumabSatralizumabTime frame: Week 48
  • EditedArea underUnder the concentrationConcentration-time curveCurve [AUC] of satralizumabSatralizumabTime frame: Week 48
Oct 1, 2026
Secondary outcomes
8 edited
What changed in the outcomes
  • EditedProportion of relapseRelapse-free patientsParticipants by Week 48Time frame: Week 48
  • EditedAnnualized relapse rateRelapse Rate (ARR), defined as the average number of relapses for each year of the studyTime frame: Week 48
  • EditedTime to first relapseFirst Relapse (TFR) after randomizationenrollment, defined as the time from randomizationenrollment until the first occurrence of relapse, as determined by the investigatorTime frame: Week 48
  • EditedTime to relapse requiring rescue therapyRelapse Requiring Rescue TherapyTime frame: Week 48
  • EditedChange from baselineBaseline in visual acuityVisual Acuity at Weeks 24 and 48Time frame: Baseline, Week 24, Week 48
  • EditedChange from baselineBaseline in FACES Pain Rating Scale at Weeks 24 and 48Time frame: Baseline, Week 24, Week 48
  • EditedChange from baselineBaseline in EuroQol 5-Dimension, Youth (EQ-5D-Y) scoreScore and its proxyProxy at Weeks 24 and 48Time frame: Baseline, Week 24, Week 48
  • EditedIncidence and severitySeverity of adverse eventsAdverse EventsTime frame: Week 48
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    2 sites added, 1 site removed
    Show 2 added (1 Mexico, 1 Poland)
    • Hospital Infantil de Mexico Federico Gomez · Mexico City, Mexico
    • Uniwersyteckie Centrum Kliniczne · Gdansk, Poland
    Show 1 removed
    • Uniwersyteckie Centrum Kliniczne · Gda?sk, Poland
    Eligibility 2 inclusion criteria edited, 1 added; 1 exclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedDocumented history of a positive anti-AQP4 antibody test or a positive anti-AQP4 antibody test at screening;
    • EditedNeurological stability for >=30 days prior to both screening and baseline
    • EditedFor patientsparticipants receiving a baseline immunosuppressant treatment and planning to continue on these therapies, treatment must be at stable dose for 4 weeks prior to baseline
    Exclusion criteria
    • AddedIVIg or subcutaneous Ig (SCIg) within 4 weeks prior to enrollment/Day 1
    Primary outcomes 4 edited
    What changed in the outcomes
    • EditedSummary of observed serum concentration [Cthrough]Observed Serum Concentration of satralizumabSatralizumabTime frame: Week 48
    • EditedApparent clearanceClearance [CL/F] of satralizumabSatralizumabTime frame: Week 48
    • EditedApparent volumeVolume of distributionDistribution [V/F] of satralizumabSatralizumabTime frame: Week 48
    • EditedArea underUnder the concentrationConcentration-time curveCurve [AUC] of satralizumabSatralizumabTime frame: Week 48
    Secondary outcomes 8 edited
    What changed in the outcomes
    • EditedProportion of relapseRelapse-free patientsParticipants by Week 48Time frame: Week 48
    • EditedAnnualized relapse rateRelapse Rate (ARR), defined as the average number of relapses for each year of the studyTime frame: Week 48
    • EditedTime to first relapseFirst Relapse (TFR) after randomizationenrollment, defined as the time from randomizationenrollment until the first occurrence of relapse, as determined by the investigatorTime frame: Week 48
    • EditedTime to relapse requiring rescue therapyRelapse Requiring Rescue TherapyTime frame: Week 48
    • EditedChange from baselineBaseline in visual acuityVisual Acuity at Weeks 24 and 48Time frame: Baseline, Week 24, Week 48
    • EditedChange from baselineBaseline in FACES Pain Rating Scale at Weeks 24 and 48Time frame: Baseline, Week 24, Week 48
    • EditedChange from baselineBaseline in EuroQol 5-Dimension, Youth (EQ-5D-Y) scoreScore and its proxyProxy at Weeks 24 and 48Time frame: Baseline, Week 24, Week 48
    • EditedIncidence and severitySeverity of adverse eventsAdverse EventsTime frame: Week 48
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05199688
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
May 6, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Sep 12, 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

Reference Study ID Number: WN41733 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S.)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
global.medical_information@roche.com
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Satralizumab

Start the discussion